abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX)

abrdn plc lifted its position in shares of Immatics (NASDAQ:IMTX - Free Report) by 49.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 347,379 shares of the company's stock after purchasing an additional 114,479 shares during the period. abrdn plc owned 0.29% of Immatics worth $2,470,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in IMTX. Texas Capital Bank Wealth Management Services Inc bought a new position in Immatics during the 3rd quarter worth $114,000. Quarry LP grew its stake in shares of Immatics by 29.4% in the third quarter. Quarry LP now owns 11,000 shares of the company's stock valued at $126,000 after acquiring an additional 2,500 shares in the last quarter. AlphaCentric Advisors LLC increased its position in Immatics by 25.0% during the third quarter. AlphaCentric Advisors LLC now owns 25,000 shares of the company's stock worth $285,000 after acquiring an additional 5,000 shares during the period. Point72 Asset Management L.P. bought a new position in Immatics during the third quarter worth about $298,000. Finally, The Manufacturers Life Insurance Company raised its stake in Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company's stock worth $1,880,000 after purchasing an additional 13,997 shares in the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on IMTX. Bank of America lowered their target price on shares of Immatics from $16.00 to $15.00 and set a "buy" rating on the stock in a report on Tuesday, November 19th. The Goldman Sachs Group upgraded Immatics to a "strong-buy" rating in a research note on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $16.67.

Immatics Trading Up 0.4 %

IMTX stock traded up $0.02 during mid-day trading on Thursday, hitting $5.09. The stock had a trading volume of 1,424,756 shares, compared to its average volume of 1,184,836. The firm has a fifty day simple moving average of $6.39 and a 200 day simple moving average of $8.97. The firm has a market capitalization of $607.54 million, a P/E ratio of -7.71 and a beta of 0.75. Immatics has a 52 week low of $4.85 and a 52 week high of $13.77.

Immatics Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.